Uniquely modified RNA oligonucleotides targeting STAT3 suppress melanoma growth both in vitro and in vivo

Cancer Biology and Therapy

Volumn 8, Issue 21, 2009, Pages 2065-2072

  Yang, Lifang ^a   Ma, Xiaoqian ^a   Xiao, Lanbo ^a   Tang, Min ^a   Weng, Xinxian ^a   Sun, Lunquan ^b   Cao, Ya ^a,b  

^a Central South University   (China)

^b UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

Author keywords

Anti cancer; Melanoma; Modified RNA oligonucleotides; STAT3; Targeting

Indexed keywords

2' O METHYL 3' BUTANOL; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; COMPLEMENTARY RNA; OLIGONUCLEOTIDE; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; BIOLOGICAL ACTIVITY; CANCER CELL; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; ENZYME INHIBITION; GENE EXPRESSION; GENE TARGETING; GENETIC STABILITY; GENETIC TRANSFECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT;

EID: 73549092700     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.21.9839     Document Type: Article

References (31)

1. Smalley KS, Herlyn M. Targeting intracellular signaling pathways as a novel strategy in melanoma therapeutics. Ann N Y Acad Sci 2005; 1059:16-25.
2. Sahu NK, Shilakari G, Nayak A, Kohli DV. Antisense technology: a selective tool for gene expression regulation and gene targeting. Curr Pharm Biotechnol 2007; 8:291-304.
3. Redell MS, Tweardy DJ. Targeting transcription factors for cancer therapy. Curr Pharm Des 2005; 22:2873-87.
4. Kortylewski M, Jove R, Yu H. Targeting STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev 2005; 24:315-27.
5. Lewis HD, Winter A, Murphy TF, Tripathi S, Pandey VN, Barton BE. STAT3 inhibition in prostate and pancreatic cancer lines by STAT3 binding sequence oligonucleotides: differential activity between 5' and 3' ends. Mol Cancer Ther 2008; 6:1543-50.
6. Sun X, Zhang J, Wang L, Tian Z. Growth inhibition of human hepatocellular carcinoma cells by blocking STAT3 activation with decoy-ODN. Cancer Lett 2008; 2:201-13.
7. Weerasinghe P, Garcia GE, Zhu Q, Yuan P, Feng L, Mao L, et al. Inhibition of Stat3 activation and tumor growth suppression of non-small cell lung cancer by G-quartet oligonucleotides. Int J Oncol 2007; 1:129-36.
8. Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, Huang M, et al. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res 2006; 1:11-9.
9. Nikitakis NG, Hamburger AW, Sauk JJ. The nonsteroidal anti-inflammatory drug sulindac causes downregulation of signal transducer and activator of transcription 3 in human oral squamous cell carcinoma cells. Cancer Res 2002; 4:1004-7.
10. Shah NG, Trivedi TI, Tankshali RA, Goswami JA, Jetly DH, Kobawala TP, et al. Stat3 expression in oral squamous cell carcinoma: association with clinicopathological parameters and survival. Int J Biol Markers 2006; 3:175-83.
11. Yu H, Jove R. The STATs of cancer - new molecular targets come of age. Nat Rev Cancer 2004; 4:97-105.
12. Xie TX, Huang FJ, Aldape KD, Kang SH, Liu M, Gershenwald JE, et al. Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res 2006; 66:3188-96.
13. Kreis S, Munz GA, Haan S, Heinrich PC, Behrmann I. Cell density dependent increase of constitutive signal transducers and activators of transcription-3 activity in melanoma cells is mediated by Janus kinases. Mol Cancer Res 2007; 5:1331-41.
14. Li WC, Ye SL, Sun RX, Liu YK, Tang ZY, Kim Y, et al. Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3. Clin Cancer Res 2006; 23:7140-8.
15. Jing N, Tweardy DJ. Targeting Stat3 in cancer therapy. Anticancer Drugs 2005; 6:601-7.
16. Niu G, Bowman T, Huang M, Shivers S, Reintgen D, Daud A, et al. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 2002; 21:7001-10.
17. Tang GS, Cai JM, Ni J, Xiang YS, Cui JG, Zhu D, et al. Effects of STAT3 antisense oligodeoxynucleotides on apoptosis and proliferation of mouse melanoma cell line B16. Ai Zheng 2006; 25:269-74.
18. Niu G, Shain KH, Huang M, Ravi R, Bedi A, Dalton WS, et al. Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. Cancer Res 2001; 61:3276-80.
19. Wu Y, Zhang G, Li Y, Jin Y, Dale R, Sun Lq, et al. Inhibition of highly pathogenic avian H5N1 influenza virus replication by RNA oligonucleotides targeting NS1 gene. Biochem Biophys Res Commun 2008; 365:369-74.
20. Liu CM, Yang Z, Liu CW, Wang R, Tien P, Dale R, et al. Effect of RNA oligonucleotide targeting Foxo-1 on muscle growth in normal and cancer cachexia mice. Cancer Gene Ther 2007; 14:945-52.
21. Kurreck J. Antisense technologies: Improvement through novel chemical modifications. Eur J Biochem 2003; 8:1628-44.
22. Scherer LJ, Rossi JJ. Approaches for the sequencespecific knockdown of mRNA. Nat Biotechnol 2003; 12:1457-65.
23. Benimetskaya L, Takle GB, Vilenchik M, Lebedeva I, Miller P, Stein CA. Cationic porphyrins: novel delivery vehicles for antisense oligodeoxynucleotides. Nucleic Acids Res 1998; 26:5310-7.
24. Yang LF, Zhao Y, Zeng L, Gong JP, Cao Y. hTERT/re-Caspase-3 System Induce Apoptosis in hTERT-Positive Cancer Cells. Cancer Biol Ther 2006; 5:1546-53.
25. Beisner J, Dong M, Taetz S, Piotrowska K, Kleideiter E, Friedel G, et al. Efficient telomerase inhibition in human non-small cell lung cancer cells by liposomal delivery of 2'-O-methyl-RNA. J Pharm Sci 2008; 98(5):1765-74.
26. Goethe JW, Bittova M, Vogel JU, Kotchekov R, Doerr HW, Cinati Jr. Antisense oligonucleotide ISIS 2922 targets IE-expression and prevents HCMV-IEinduced suppression of TSP-1 and TSP-2 expression. Nucleosides Nucleotides Nucleic Acids 2001; 20:1425-8.
27. Dias N, Stein CA. Antisense oligonucleotides: Basic concepts and mechanisms. Mol Cancer Ther 2002; 5:347-55.
28. Raoof AA, Chiu P, Ramtoola Z, Cumming IK, Teng C, Weinbach SP, et al. Oral Bioavailability and Multiple Dose Tolerability of an Antisense Oligonucleotide Tablet Formulated with Sodium Caprate. J Pharm Sci 2004; 93:1431-9.
29. Traynor K. Antisense drugs progressing through product pipelines. Am J Health Syst Pharm 2002; 59:2046-7.
30. Geary RS, Henry SP, Grillone LR. Fomivirsen: clinical pharmacology and potential drug interactions. Clin Pharmacokinet 2002; 41:255-60.
31. Bennett MD, Yee W, Bryan JS. Pegaptanib combined with intravitreal injection of moxifloxacin as treatment of wet macular degeneration. Retina 2008; 28:976-80.